December 9, 2016
Valneva to test its Lyme disease vaccine
Valneva said on Friday it will sent its Lyme disease vaccine candidate VLA15 to clinic. Phase I testing can begin…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 9, 2016
Allergan dissapointed with PTAB’s reaction as Mylan petitions for IPR of Restasis patents
Allergan said on Thursday that it was disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that…
December 9, 2016
Alzheimer’s disease drug study disappoints Lilly
Eli Lilly has presented detailed results of its disappointing phase 3 Expedition3 trial at the 9th Clinical Trials on Alzheimer’s…
December 8, 2016
Horizon quits Friedreich’s ataxia treatment study
Horizon Pharma has announced that the Phase 3 trial, Steadfast (Safety, Tolerability and Efficacy of Actimmune Dose Escalation in Friedreich’s Ataxia study), evaluating Actimmune (interferon gamma-1b) for…
December 8, 2016
EMA to review Sanofi/Regeneron’s skin disease treatment Dupixent
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application…
December 8, 2016
Novartis gets eye disease drug European approval
European Commission (EC) has granted an additional indication for Novartis’s Lucentis (ranibizumab) to treat patients with eye disease due to…
December 8, 2016
Erytech places shares, funds acute leukemia drug
Acute leukemia focused pharmaceutical company Erytech Pharma, has announced the closing of a private placement of 793,877 ordinary shares to…
December 8, 2016
Novartis gets positive COPD related study results
Novartis on Wednesday announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating…
December 8, 2016
Bristol-Myers raises its quarterly dividend
Bristol-Myers Squibb Company has declared an increase of 2.6% percent in the its quarterly dividend, beginning in the first quarter…
December 8, 2016
ValiRx’s prostate cancer drug gets European patent
European Patent Office has granted ValiRx’s patent covering its major therapeutic compound VAL201, including prostate cancer, the pharmaceutical company said on…